References
- 1. Julius U, Tselmin S, Schatz U, Fischer S. Birkenfeld AL, Bornstein SR. Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels. Atheroscler Suppl. 2019;40:1-7.10.1016/j.atherosclerosissup.2019.08.04331818437
- 2. Yu RZ, Graham MJ, Post N, et al. Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein(a) in Mice. Mol Ther Nucleic Acids. 2016;5:e317.10.1038/mtna.2016.26501451227138177
- 3. Wu MF, Xu KZ, Guo YG, Yu J, Wu Y, Lin LM. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives. Cardiovasc Drugs Ther. 2019;33:739-748.10.1007/s10557-019-06906-931655942
- 4. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med. 2020;382:244-255.10.1056/NEJMoa190523931893580
- 5. Clarke R, Peden JF, Hopewell JC, et al. Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease. N Engl J Med. 2009;361:2518-2528.10.1056/NEJMoa090260420032323
- 6. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther. 2010;126:314-345.10.1016/j.pharmthera.2010.01.00820153365
- 7. Rifai N, Ma J, Sacks FM, et al. Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: the Physicians’ Health Study. Clin Chem. 2004;50:1364-1371.10.1373/clinchem.2003.03003115155542